INS and Alzheimer disease: In addition, the modulatory effects of APOEε4 may be related to insulin sensitivities, as lower CSF insulin levels and lower insulin sensitivities have been observed in non-ε4 carriers with AD compared to ε4 carriers [128,129], and, thus, noncarriers may benefit the most from restoring insulin signalling within the brain.